Nymox Pharmaceutical Corporation (NYMX) released long-term clinical trial outcome from the Company’s NX-1207 Phase 2 prostate cancer study NX03-0040. The new outcome demonstrate statistically noteworthy (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients contrast to controls. Trial participants comprised of 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites.
rebeccaherbstinvestor_fan1: I'm a war veteran you jerk!
I feel like crying.
They're going to get fat!
Recordati posts sales growth and significant margin improvement in 1st
The Pharma Letter
In February, an exclusive license agreement was entered into with USA-based Apricus Biosciences for the marketing and sales of Vitaros (alprostadil), .